PhRMA Renews Legal Challenge To 340B Orphan Drug Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
HRSA issued an “interpretive” rule pertaining to discounts on orphan drugs in 340B after a federal judge invalidated the same policy as a “legislative” rule. Now, the pharma trade group asks the court to reject the policy in its “interpretive” form.
You may also be interested in...
340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request
HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.